Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.18, moving -3.34% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.57%.

Recursion Pharmaceuticals (RXRX) is back in focus as investors weigh fresh updates on its AI-driven drug discovery platform, along with progress in key clinical assets REC-1245 and REC-4881 and ...

The stock looks cheap, but appearances can be deceiving.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the 9 Stocks Crushing the Market With Surging Returns. Recursion Pharmaceuticals snapped two straight days of losses on Thursday, surging 9.51 ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 16.2% in that time frame, outperforming the S&P 500. But investors have to be ...

AI drug pioneer Recursion Pharmaceuticals said Wednesday that one of its experimental treatments hit a key milestone. Recursion was able to use its artificial intelligence-enabled drug discovery ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of ...

Salt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...